TO THE EDITOR-In their letter, Cannizzo et al [1] highlight an important issue in the interpretation of T-cell activation marker data in the context of human immunodeficiency virus (HIV) infection. CD38 has long been interpreted as a Tcell activation marker in HIV infection, but resting naive T cells may also express low-to-moderate amounts of this surface marker. Indeed, CD38 (then known as "T10") was first demonstrated to be dramatically elevated on T cells from untreated HIV-infected individuals in 1981 [2] , in one of the first published reports to describe AIDS and years before HIV was discovered as the cause of AIDS. Subsequently, work by Giorgi et al [3] Nevertheless, most studies of T-cell activation in treated HIV infection, including our own recent study [4] and the article by Tenorio et al [5] referred to in the letter by Cannizzo et al [1] , use CD38 coexpression with HLA-DR to identify activated T cells. Since HLA-DR is not typically expressed on resting naive cells, coexpression of HLA-DR and CD38 typically identifies activated memory T cells. It should also be noted that we observed a significant relationship between both CD4 + and CD8 + T-cell activation and mortality in this study, although these associations were attenuated after adjustment for current CD4 + T-cell count, suggesting that the relationship between T-cell activation and mortality may be at least in part mediated and/or confounded by the degree of ART-mediated CD4 + T-cell recovery. Nevertheless, markers of innate immune activation and inflammation predicted mortality much more strongly than T-cell activation in our study (as well as in the study by Tenorio et al), suggesting that innate immune activation may be a more appropriate target than T-cell activation for interventions to reduce mortality in this setting. Last, while we do not believe that naive T-cell expression of CD38 affected the relatively weak association between Tcell activation and clinical outcomes in these 2 studies, we acknowledge the possibility that T-cell activation, as a marker of adaptive immune defects, may be a better predictor of AIDS and infectious complications than it is of cardiovascular and other causes of death that may predominate in North American studies. Indeed, recent work from the SUN study suggests that monocyte activation more strongly predicts progression of atherosclerosis progression (by coronary calcium score) than T-cell activation in treated HIV infection [6] . Conversely, we have observed much stronger relationships between T-cell activation and mortality in HIV-infected Ugandans during early ART-mediated viral suppression (a setting where individuals are more likely to die from infectious complications) than we have in the North American cohorts [7] . These observations underscore the need for parallel biomarker research in both resource-rich and resource-limited settings, as the specific immunologic pathways that are most important in driving morbidity and mortality (and the interventional targets they may suggest) may differ between these settings.
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